尽管收入为320K美元,但CervoMed却损失了0.84美元的股权,而输油管承诺和内幕购买的股票却在上涨。 CervoMed lost $0.84/share despite revenue of $320K, yet stock rose on pipeline promise and insider buying.

CervoMed Inc.报告,每股季度损失0.84美元,收入为320 000美元,未达到预期值。 CervoMed Inc. reported a quarterly loss of $0.84 per share, missing expectations, on $320,000 in revenue. 这家生物技术公司开发治疗包括痴呆症在内的神经系统疾病，利用路易氏体和阿尔茨海默病，尽管盈利未达预期，其股价仍上涨至5.31美元。 The biotech company, developing treatments for neurologic disorders including dementia with Lewy bodies and Alzheimer’s, saw its stock rise to $5.31 despite the earnings miss. 分析师认为"适度购买"的共识是22.17美元,并指出该公司有潜力,包括首选药物内夫拉皮莫德和临床前化合物EIP200. Analysts maintain a "Moderate Buy" consensus with a $22.17 target, citing potential in its pipeline, including lead candidate neflamapimod and preclinical compound EIP200. 内幕购买大幅增长,首席执行官John J. Alam在11月将股份提升632%。 Insider buying has increased significantly, with CEO John J. Alam boosting his stake by 632% in November.